Drug Profile
JSM 6427
Alternative Names: JSM-6427Latest Information Update: 04 Mar 2011
Price :
$50
*
At a glance
- Originator Jerini Ophthalmic
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Integrin alpha 5 beta 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Age-related macular degeneration; Proliferative vitreoretinopathy
Most Recent Events
- 04 Mar 2011 Development discontinued for Age-related macular degeneration during 2010
- 10 Apr 2008 Jerini Ophthalmic signs an exclusive licensing and development agreement with PR Pharmaceuticals to develop sustained-release formulations, including JSM 6427 for the treatment of age-related macular degeneration
- 07 Dec 2007 Jerini Ophthalmic enters into a research collaboration agreement with University College London Institute of Ophthalmology for the development of JSM 6427 in age-related macular degeneration